KeyBanc analyst Scott Schoenhaus lowered the firm’s price target on Progyny to $45 from $55 to reflect his new target multiple of 4.0-times his target fiscal 2023 revenue estimate. The analyst keeps an Overweight rating on the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PGNY: